Daraxonrasib Phase 3 Data Draws Attention at ASCO, Potential Turning Point for Second-Line Pancreatic Cancer Treatment
After the U.S. FDA allowed expanded access to daraxonrasib, Phase 3 survival data at the ASCO meeting explained why this RAS inhibitor is drawing intense attention; however, it is still not a formally approved therapy, and its efficacy, safety, and appropriate patient population remain subject to full review.